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INTRODUCTION 
Maintenance of a balance or homeostasis of metabolic functions in all 
body organs is critical in the humans . This balance is achieved by actions 
of  hormones. Thyroid hormones affects growth and differentiation of  cells 
and  modulate important functions in virtually all cells, tissues and organs. 
 
 kidney is involved in metabolic waste excretion, maintenance of fluid 
and acid base balance by regulating the concentration of hydrogen, sodium, 
potassium, phosphate and other ions in the extracellular fluid, secretion and 
metabolism of hormones which are important in haemodynamic control,  
erythrocyte production and metabolism of various minerals. 
 
Chronic Kidney Disease (CKD) is a worldwide public health and 
health care problem with an increasing  prevalence, poor outcomes, 
mortality and high cost. 
 
Chronic Kidney disease (CKD) includes a spectrum of different 
pathologic and physiologic processes which are associated with 
progressive decrease in  GFR. 
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It is a disease process that is associated with early death of patients 
and  reduced  quality of life.  A trend towards an raise in its occurance and 
prevalence has been reported worldwide, as  epidemics in some countries 
and regions.  
 
Adverse  effects of CKD such as renal  failure, cardiovascular disease 
and  mortality can be prevented or delayed. Early stages of CKD can be 
screened through laboratory testing and if treated effectively, it would 
slowdown progression towards kidney failure  and cardiovascular disease.  
 
Improving the future of  CKD patients would require a co-ordinated   
approach for prevention  of  adverse effects by identifying the disease at 
early stages, determine its burden on the community, identify  risk factors, 
treatment of at risk populations. 
 
Chronic kidney disease is a clinical syndrome characterized by 
irreversible dysfunction of kidneys that ultimately results in excretory, 
metabolic and synthetic failure that leads to death without renal 
replacement therapy. 
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           The complex interaction of the kidney and thyroid gland is well 
studied. Kidney metabolizes  and eliminates thyroid hormones in humans. 
The growth and development of kidney,  water and  electrolyte 
homeostasis requires action of thyroid hormones. 
 
The knowledge of metabolic and hormonal abnormalities in milder 
degrees of renal dysfunction is growing but only little is known about 
thyroid dysfunction in CKD patients. The literature available regarding 
thyroid dysfunction in chronic disease  on conservative management is still 
low. 
 
Patients with advanced CKD has symptoms like easyfatigueability, 
lethargy,  cognitive decline and sexual dysfunction, that considerably 
overlaps with hypothyroidism  but only a few studies are done so far about 
the prevalence or severity of thyroid dysfunction in patients with CKD. 
 
Thyroid hormones are important for  growth and differentiation, and 
modulation of physiological functions in all the tissues including the 
kidney. They also play a vital role in water and electrolyte homeostasis. 
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  Either hypo or  hyperthyroidism is accompanied by modulations in 
water and electrolytes metabolism , as well as cardiovascular function. 
kidney is a target organ for thyroid hormone  and for the metabolism and 
elimination of  hormones.  
 
          Decline in kidney function is associated with abnormalities in the 
thyroid hormone functions. CKD affects both HPT axis and thyroid 
hormone’s catabolism. These effects of reduced renal function may lead to 
hypothyroidism, hyperthyroidism and non-thyroidal illness which are 
associated with  cardiovascular dysfunction which will have adverse 
effects on the prognosis of CKD. 
 
The importance of knowing the prevalence of thyroid dysfunction in 
CKD patients lies in the fact that it adds to already high cardiovascular 
mortality risk in this patients group. 
 
This original research was under taken to study the thyroid 
dysfunction that occurs in CKD patients not on maintenance dialysis. 
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AIMS AND OBJECTIVES 
 
 To study thyroid function tests in chronic kidney disease patients on 
conservative management. 
 To study the proportion of thyroid dysfunction in chronic kidney 
disease patients on conservative management. 
 To study the correlation between the severity of renal dysfunction 
with thyroid abnormality. 
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REVIEW OF LITERAURE 
 
REVIEW ANATOMY & PHYSIOLOGY: 
GROSS ANATOMY: 
Kidneys are two in number located in the retroperitoneal space. The 
Kidneys extended vertically from T12 to L3 vertebra. 
 
DIMENSIONS: 
Each adult Human Kidney weighs about 130  to 180 grams in males and 
110 to 160 grams in females. It is 10 to 13 cm in length, 5 to 8 cm in 
breadth and 2 to 3.0 cm thick. 
 
MICROSCOPIC ANATOMY: 
The complex structure of mammalian kidney can be simplified as a 
unipapillary model. The unipapillary kidney consists of a cortex and 
medulla. The kidney of humans contains about 1 million nephrons. 
 
NEPHRONS: 
Main segments of nephron include glomerulus, renal tebule and 
collecting duct. 
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GLOMERULUS: 
The glomerulus has special capillaries to mesangium, which is enclosed 
in the glomerular (Bowman) capsule. The epithelial cells (podocytes), 
covers the mesangium and capillaries forming the visceral epithelium of 
bowman capsule. 
FIGURE 1 - GLOMERULUS 
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Between glomerular capillaries, mesangium and the podocytes layer, 
the glomerular basement membrane (GBM) develops. On entering the 
glomerular tuft, the afferent  arteriole divides and forms an anatomizing 
capillary network representing a glomerular lobule. 
 
RENAL TUBULE: 
The real tubule comprises of convoluted tubules proximal and distal ,  
henle’s loop, the collecting duct. The henle’ loop comprises of thin 
descending  and ascending  limbs and  thick ascending limb. Two different 
pathways exist. A transcelluar pathway across the luminal, basolateral 
memberanes, and cytoplasm and paracelluar pathway through the 
junctional and intercellular spaces. 
 
COLLECTING DUCT: 
The collecting duct includes cortical, outer & inner medullary collecting 
duct. Principal (light) cells and intercalated (dark) cells are the two types of 
cells in collecting duct. The collecting duct plays crucial role in handling 
Na+, Cl- and K+ and acid in response to vasopressin can or dilute urine. 
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MICROVASCULATURE: 
The renal artery divides into interlobar arteries after entering the renal 
sinus. At cortico medullary junction, the interlobar arteries divide into the 
arcuate arteries, which branch into cortical radial arteries. 
Afferent arterioles supply the glomerular tufts and generally arise 
from cortical radial arteries. The blood supply of the peritubular capillaries 
is mainly postglomerular. 
The efferent arterioles drain the glomerulus. Cortical efferent 
arterioles, from superficial and mid cortical glomeruli, supplies cortex. The 
efferent arteriole  supplies the renal medulla. In  outer stripe of the 
medulla, these vessels divide into the descending vasa recta. 
 
FIGURE 2 – STRUCTURE OF NEPHRON 
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CHRONIC KIDNEY DISEASE 
 
Chronic kidney disease (CKD) entails the presence of kidney 
damage or decreased level of function for 3 months or more. While no 
local prevalence data exist, the risk factors such as post-streptococcal 
glomerulonephritis, hypertension, diabetes and lately HIV associated 
nephropathy (HIVAN) are on the rise. Recent studies show that early 
diagnosis allows for institution of therapy to either arrest or reverse 
progression of the global challenge that CKD has become.  
 
In 2000, the National Kidney Foundation (NKF), and  Kidney 
Disease Outcome Quality Initiative (KDOQI) Advisory Board approved 
clinical practise guidelines to define CKD and to classify stages in the 
progression of CKD based on eGFR. 
 
Glomerular diseases such as post-streptococcal glomerulonephritis 
contribute to a large proportion of early CKD. Chronic pyelonephritis and 
tuberculosis are notable infectious risk factors of which HIV-associated 
nephropathy is routinely encountered. Congenital anomaliese.g. polycystic 
kidney disease and obstructive processes such as calculi are also culpable 
causative factors. Collagen disease e.g. SLE and vascular diseases such as 
renal nephrosclerosis may also lead to CKD. Nephrotoxic agents e.g. 
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aminoglycoside therapy are occasionally implicated. Chronic kidney 
disease may be a progression from acute renal failure. 
 
   GFR  is widely accepted as the best  measure for renal function in 
health and disease. Providers and patients are familiar with the concept  
that “the kidney is like a filter.” The ‘gold standard’ of measuring GFR is 
by the renal clearance of exogenous markers Inulin, radio-labelled EDTA 
(51Cr-EDTA) and technecium-labelled diethylene-triaminepentacetate( 
99mTc-DTPA) and iohexol.  
 
These tests are however time-consuming, labour intensive,invasive, 
costly and require specialized equipment restricting their use in routine 
individual cases monitoring or in large epidemiological studies. While an 
ideal endogenous marker should meet 3 criteria of complete filtration at the 
glomerulus, absent tubular secretion and no tubular reabsorption, serum 
creatinine is widely accepted as an endogenous marker for assessing renal 
function.  
 
Currently, a spot serum creatinine level is favoured with creatinine-
based equations for estimating GFR being employed. They include; the 
Cockcroft-Gault (CG), the 4-variable Modifications of Diet in Renal 
Disease (4v-MDRD) and the Mayo Clinic Quadratic formulae.  
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These equations are used interchangeably to suit various study 
populations. Most CKD patients tend to progress over time and worsen. 
The risk of adverse outcomes in CKD can be further stratified by the 
severity of disease and rate of progression. 
 
 The outcomes of CKD include loss of kidney function leading to 
kidney failure and development of cardiovascular disease. 
 
The evaluation and management of CKD as recommended by the 
work group includes  treatment of co-morbid illness, preventing  the loss of 
kidney failure and delay disease process, preventing and early treatment of 
cardiovascular disease,  preventing and early treatment of complications of 
decreased renal function and early initiation of dialysis to replace renal 
function and plan for renal transplantation in possible patients. 
 
            Thus CKD is a disease process in which early diagnosis and proper 
follow up to control risk factors will reduce the progression of renal 
dysfunction. 
 
 
 
13 
 
 
ESTIMATION OF KIDNEY FUNCTION: 
 
The current CKD classification is based on eGFR. The Modification 
of Diet in Renal Disease (MDRD) study equation and the more recently 
developed Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation are both commonly used equations to calculate eGFR; 
however, both are relatively inaccurate in reflecting measured glomerular 
filtration rate (mGFR) above 60 ml/ min/1.73 m2. This underestimation by 
eGFR of true mGFR can lead to misclassification of a large number of 
individuals as having CKD stage 3a, whereas in reality their true GFR is 
above 60 ml/min. Also, the inaccuracy of eGFR to reflect mGFR above 60 
ml/min/1.73 m2 makes the distinction between CKD stages 1 and 2 
difficult and  artificial. The limitations of using creatinine-based 
estimations have spurred the search for alternative filtration biomarkers, 
such as β- trace protein (βTP), cystatin C, and β2-microglobulin (β2M) 
 
GLOMERULAR FILTRATION RATE: 
MDRD (Modification of Diet in Renal Disease Equation) 
GFR (mL / min / 1.73 m3) = (Scr)-1.154 x (Age)-0.203 x (0.742 if 
African America) 
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The results of this equation are reported normalized to 1.73 m2 body 
surface area, which is an accepted adult surface area which eliminates the 
need for knowing accurate weight and height variables. 
 
RISK FACTOR: 
• Age (older) 
• Race of ethnicity (Non – Caucasian) 
• Genetics 
• Birth weight (low) 
• Systemic hypertension 
• Diabetes mellitus 
• Cardiovascular disease 
• Albuminuria 
• Obesity or metabaolic syndrome 
• Dyslipidemia 
• Hyperuricemia 
• Smoking 
• Low socioeconomic status 
• Nephrotoxin exposure: non steroidal anti-inflammatory drugs 
(NSAIDs), lead, traditional herbal use. 
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PATHOPHYSIOLOGY: 
Kidney scarring or fibrosis is a complex, overlapping, multistage 
phenomenon that could be characterized by a number of processes:  
■ An inflammatory response with infiltration of damaged kidneys by 
extrinsic inflammatory cells (blood borne and bone marrow derived)  
 
■ Activation, proliferation, and loss of intrinsic renal cells (through 
apoptosis or necrosis and including mesangiolysis and podocytopenia)  
 
■ Activation and proliferation of extracellular matrix (ECM)–producing 
cells, including myofibroblasts and fibroblasts  
 
■ Deposition of ECM replacing the normal renal architecture 
 
INITIATION OF INJURY: 
The underlying initiates the renal damage by specific mechanism 
(eg., genetically determined abnormalities, immune complex deposition, or 
toxin exposure) which leads to adaptive changes. 
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PROGRESSION OF DAMAGE: 
The hyperfiltration and hypertrophy of the remaining functioning 
nephrons occurs in response to injury which in long-term leads to reduction 
of renal mass, irrespective of underlying aetiology. These maladaptive 
leads to sclerosis and dropout of the remaining nephrons. This eventually 
leads to progressive decline in renal function over many years. 
 
RECOMMENDED KIDNEY PROTECTIVE THERAPIES: 
LEVEL 1 RECOMMENDATIONS  
1. Control blood pressure (BP). 
           2. Administer ACE inhibitor,  ARB , or renin inhibitor.  
     3. Avoid dihydropyridine calcium channel blockers (DHCCBs) 
unless needed for BP control 
 4. Control protein intake. 
 
LEVEL 2 RECOMMENDATIONS  
1. Restrict NaCl intake and use diuretics. 
 2. Administer NDHP-CCB therapy. 
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 3. Control each characteristics of the metabolic syndrome. 
 4. Administer aldosterone antagonist therapy. 
 5. Administer allopurinol therapy 
 6. Control serum phosphorous. 
 7. Instigate smoking cessation. 
 8. Perform alkali therapy. 
 9. Administer β-blocker therapy.  
10. Avoid overanticoagulation with warfarin. 
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DEFINITION OF CHRONIC KIDNEY DISEASE: 
Criteria for CKD (either of he following present for > 3 months) 
I. Markers of kidney damage (one or more) 
• Albuminuria (AER ≥ 30 mg/24 hours; ACR ≥ 30 mg/g) 
• Urine sediment abnormalities 
• Electrolyte and other abnormalities due to tubular disorders 
• Abnormalities detected by histology 
• Structural abnormalities detected by imaging 
• History of kidney transplantation 
 
II. Decreased GFR – GFR < 60 ml/min/1.73 m2 
Abbreviations:  
ACR – Albumin to Creatinine Ratio, AER – Albumin Excretion 
Ratio 
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STAGING KIDNEY DISEASE: 
 
TABLE 1 
 
GFR 
CATEGORY 
eGFR 
(ml/min/1.73 
m2) 
Terminology 
G1 < 90 Normal to High 
G2 60 – 89 Mildly decreased 
G3a 45 – 59 Mild to moderately decreased 
G3b 30 – 44 Moderately to severely decreased 
G4 15 – 29 Severely decreased 
G5 < 15 Renal failure 
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COMPLICATION OF CKD: 
The complication of chronic kidney disease increases with 
progression of disease. The prevalence of complications in stage 1 CKD is 
0.28, and it rises to an average of 1.71in stage 4. 
 
The well know complications of CKD are as follows, 
• Anemia 
• Bone-mineral disorder 
• Metabolic acidosis 
• Cardio – vascular risk 
• Dyslipidaemia 
• Nutritional deficiency 
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THYROID SYNTHESIS AND PHYSIOLOGY: 
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        The thyroid is unique among the endocrine glands by virtue of the 
large store of hormone it contains the low rate at which the hormones 
turnover (1 % per day). Iodine is ingested in both inorganic and organic 
bound forms. Iodine is rapidly and efficiently absorbed from the 
gastrointestinal tract. 
The thyroid gland produces two related hormones, thyroxine (T4) and 
Triiodothyrone (T3).Acts through nuclear receptors, these hormones play a 
vital role in cell differentiation and help maintain  homeostasis in the adult. 
Thyriod stimulating hormone (TSH), secreted by the anterior pituitary 
is responsible for control of the thyroid axis. Thyroid hormones are derived 
from thyroglobulin, a  glycoprotein, which is iodinated on tyrosine 
residues.  
T4 is secreted from the thyroid gland in about 20 times  more than T3. 
Both hormones bind to proteins in the plasma like thyroid-binding globulin 
(TBG); transthyretin (TTR, also known as thyroxine-binding prealbumin, 
or TBPA); and albumin. These  proteins increase the levels of circulating 
hormones, reduce its clearance, and  modulate delivery of hormones to 
various tissue sites. When the effects of various binding proteins are 
combined, app 99.98% of T4 and 99.7% of T3 are bound to proteins. T4 is 
converted to T3 by the de-iodinase enzymes.  
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T4 to T3 conversion is reduced by fasting, systemic illness anda 
variety of medications including propyl thiouracil, propranolol, 
amiodarone, glucocorticoids. Type III de-iodinase inactivates T4 and T3 
and is the most important source of reverse T3 (rT3) 
 
IODINE TRAPPING: 
It is then actively transformed into the thyroid cell which is 
accomplished by a membrane protein called sodium-iodine symporter 
(NIS). 
 
ORGANIFICATION:  
Oxidation of iodine and incorporation of the resulting intermediate, 
covert iodine into the hormonally inactive iodotyrosines {Mono 
iodotyrosines and diiodotyrosine}. 
 
COUPLING:  
MIT & DIT are coupled to form T3 whereas two DIT are coupled to 
form T4. Oxidation, iodination and coupling reactions are mediated by 
heme-containing protein thyroid peroxidase (TPO). 
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SECRETION:  
The hormone produced binds with thyroglobulin till secreted. In the 
blood, it is transported in bound and free from. Most common binding 
proteins are thyroid binding globulin, prealbumin and albumin. T4 is 
predominantly bound to thyroid binding globulin whereas T3 is 
predominantly bound to albumin. The other form is free T3 & T4. These 
free forms are in equilibrium with bound form. 
 
PHERIPHERAL METABOLISM:  
In the periphery one third of T4 is converted to T3 by 5’ Deiodenase 
and 45% to rT3 by 5 Deiodenase. They are further metabolized to 
Diiodothyronines. Only about 13% of T3 is produced from thyroid gland 
and remaining 87% is formed from T4. 
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FIGURE 3 – HYPOTHALAMIC PITUITARY AXIS 
 
 
 
Two major factors control synthesis and release of TSH: 
1. T3 level within thyrotropic cells, which regulates mRNA 
expression, TSH translation. 
2. TRH, which controls posttranslational glycosylation and release. 
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OTHER FACTORS: 
TSH synthesis and release are inhibited by high serum levels of T4 
and T3 (hyperthyroidism) and stimulated by low levels of thyroid hormone 
(hypothyroidism). Somatostatin, dopamine, dopamine agonists 
(bromocriptine) and glucocortocoids and inhibit TSH secretion. Acute 
illness can inhibit TSH secretion followed by rebound rise in TSH as the 
patient recovers. 
 
From a clinical practice viewpoint, both hypothyroidism and 
hyperthyroidism are accompanied by remarkable alterations in the water 
and electrolyte metabolism, as well as in cardiovascular function.. 
 
         The major pathway of thyroid hormone metabolism is by de-
iodination and only 25% is conjugated, deaminated or decarboxylated. 
Although the liver is the major site of metabolism, the kidney also 
participates to a lesser degree by deamination and decarboxylation. Renal 
conversion of T4 to T3 and reverse T3 (rT3) also occurs. The kidney also 
is the most important  route for iodine excretion and in renal dysfunction 
the plasma levels of inorganic iodine are raised.  
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On the other hand, the different treatments used in management of  
renal disease  and thyroid diseases  may be accompanied  by adverse 
events that alter thyroid and kidney function respectively. 
 
The decrease in the activity of Thyroid hormone results in inability to 
excrete water  results in water overload, this effect is due to reduction in 
the GFR. Thyroid hormones enhance tubular transport of  Na+, via their 
actions on  Na/K ATPase  and  K+ ions in the membrane of proximal 
tubules.  
 
TH moderate renin release from the juxta glomerular cells through a 
mechanism that does not involve the ouabain-sensitive sodium pump  
effects kidney angiotensinase activity.  
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KIDNEY AND THYROID: 
The growth of the kidneys also depends upon adequate thyroid 
hormones. The kidneys also metabolize and excrete thyroid hormones. 
Thyroid abnormalities can significantly alter kidney function and fluid & 
water balance. 
FIGURE -4  : KIDNEY AND THYROID 
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EFFECT OF THYROID HORMONES IN RENAL PHYSIOLOGY: 
Thyroid hormones influences directly as well as indirectly  
1.The direct effect of thyroid hormones on 
a.glomerular filtration rate. 
b.hormonal influences on renal tubular physiology. 
c. tubular secretion and re-absorptive processes 
 
2.Indirect effects are through influence of thyroid hormones on renal blood 
flow and cardiovascular system3 
 
Thyroid hormones affect renal clearance of water,increases the activity 
of the Na/K ATPase18.  
 
Thyroid hormones also regulates the renin-angiotensin-aldosterone 
axis40. 
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EFFECT OF THYRIOD DYSFUNCTION ON KIDNEYS: 
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CHRONIC  KIDNEY DISEASE AND THYROID: 
CRD affects peripheral metabolism of thyroid hormones and 
hypothalamus-pituitary-thyroid axis19. 
 
FIGURE 5-EFFECTS OF CKD ON THYROID HORMONES 
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URAEMIA AND THYROID:20,23 
 
Uraemia causes blunted and delayed response of TSH receptors to 
TRH and altered circadian rhythm which leads to normal or elevated levels 
of TSH, indicating pituitary disturbances. The TSH glycosylation is altered 
in CKD, which compromises its activity23. 
 
Uraemia affects the volume and functions of the thyroid. Women who 
has uraemia had higher volume of thyroid and increased prevalence of 
goitre when compared to women with normal renal function. Thyroid 
carcinoma and thyroid nodules is found to be more common in uremic 
patients27. 
 
Effects of chronic kidney disease on thyroid hormone function 
Chronic kidney disease causes multiple abnormalities in the thyroid 
physiology. These include the state of chronic illness, malnutrition and 
negative nitrogen balance, the presence of circulating inhibitors of 
hormone metabolism and a multitude of hormone alterations. CKD 
interferes with H-P-T axis and also in TH metabolism. 
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 Uraemia causes dysfunction  and alters volume of the thyroid. ckd 
patients have thyromegaly compared with subjects. There is higher 
prevalence of goitre, more in women. Nodules and thyroid malignancy are 
more common in CKD patients when compared to normal population. 
 
THYROXINE 
Total T4 levels are either  normal or reduced in CKD pts,  this is due 
to  reduced  binding to the carrier proteins.  concentrations of major carrier 
proteins appears to be  normal in ckd, and it is postulated  that  
accumulations of many  Uraemic toxins reduce T4 binding  to carriers 
which causes low  T4 levels but  free t4  levels remains unaffected.  
 
The available test estimates low values of free T4.  fT4 measurement  
uses equilibrium dialysis,  dialyzable circulating inhibitors are removed. 
This inturn raises T4 binding to carriers, resulting in low free T4 levels.  
 
fT4 and total T4 either be normal, or  reduced, or sometimes the free 
T4 be high due to  heparin which used during haemodialysis, which 
inhibits T4 binding. 
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TRIIODOTHYRONINE (T3) 
 
Total and fT3  levels are reduced in CKD. The low T3 syndrome  is 
the most  observed  thyroid alteration in ckd patients. This low T3 is 
caused by  decreased  peripheral conversion of T4.  
 
Chronic metabolic acidosis is common in  CKD. This inturn  may 
further contribute to this reduced  conversion. Acumulation of uraemic 
toxins reduces binding of T3 to serum carrier proteins which leads to 
reduced T3 levels.  
 
Low  fT3 levels in uraemia is interpreted as a response to reduce   
the energy expenditure of cells  and also for minimizing  metabolism of 
proteins. 
 
Also Low T3 is indicator of mal-adaptation contributing to 
worsening  of the ckd.  
 
 Many studies  have now shown that  reduced T3 levels are 
correlated to  inflammatory markers and  now an important predictor of 
death  in ckd  patients on maintaenance dialysis.  
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THYROID STIMULATING HORMONE (TSH) 
Serum TSH is ether normal or elevated in CKD,  
 
TSH  response to its releasing hormone (TRH) is low. These 
findings suggest some intra thyroidal and pituitary disturbances are 
associated with uraemia.  
 
Circadian rhythm  of TSH secretion and glycosylation of TSH are 
affected in CKD.  Alteration In  glycosylation compromise TSH biological 
action. Both normal nuclear T3 levels and also  normal thyroid receptor 
action in pituitary explains the normal  TSH levels. 
  
This Abnormal  glycosylation of TSH ,  altered  rhythm of secretion 
and pulsatile secretion of TSH, and blunted TSH response to TRH are 
reported in Uraemic patients points to a disordered function at the 
hypothalamics level and pituitary levels. 
 
Interestingly, in Uraemic patients with primary non-immune 
hypothyroidism, TSH  may increase appropriately. 
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Free T3 Assay(fT3) 
The fT3 test is a solid phase ELISA. Patient  samples, standard 
samples, and T3 -Conjugated Working Reagent are added to wells coated 
with monoclonal T3 Ab.  
 
fT3 in the patient sample  and  conjugated T3 competes for the 
binding sites of the Ab. After 60min  period of  incubation at 37 degree,  
the wells are washed thoroughly with water to remove the unbound excess 
T3 conjugate.  
 
Then H2O2/TMB solution is added  and again incubated for another 
20 min,  till appearance of  blue color. The color developed can be stopped 
by adding 3N HCl, and  the sample now is taken for  spectro  photometry 
and viewed at 450 nm. The intensity of the color is proportional directly  to 
level of enzymes present and  inversely  to the level of unlabeled fT3. 
 
 
 Free T4 Assay 
The fT4 test is a solid phase ELISA. Patient  samples, standard 
samples, and T4-Conjugated Working Reagent are added to wells coated 
with monoclonal T4 Ab.  
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fT4 in the patient sample  and  conjugated T4 competes for the 
binding sites of the Ab. After 60min  period of  incubation at 37 degree,  
the wells are washed thoroughly with water to remove the unbound excess 
T4 conjugate.  
 
Then H2O2/TMB solution is added  to the wells and again incubated 
for  another 20 min,  till appearance of  blue color. The color developed 
can be stopped by adding 3N HCl, and  the sample now is taken for  
spectro-photometry and viewed at 450 nm. The intensity of the color is 
proportional directly  to level of enzymes present and  inversely  to the 
level of unlabeled fT4. 
. 
 
TSH Assay 
TSH assay  is  a solid phase ELISA.  
The assay systems uses the monoclonal Abs directed against the 
antigenic sites on the intact TSH molecule. 
  
Mouse monoclonal anti-TSH Ab is used for the solid phase of 
ELISA (microtiter wells), and goat anti-TSH Ab is used in Ab-enzyme 
(horse-radish peroxidase enzyme) conjugate solution.  
38 
 
 
 
The test sample is allowed to react  with the Abs, thus the TSH in the 
sample gets sandwiched between the two, the solid phase and enzyme-Ab 
complex.  
 
After a incubating  at 37 degree for 2 hour, then after shaking well, 
the solid phase then washed thoroughly with distilled water. This removes  
all the unbound labeled antibodies and leaves behind the bound TSH.  
 
A solution  of tetramethylbenzidine  added to the wells and once 
again incubated for another 20 min, which results in a  blue color. This 
color development can be stopped by adding  1N HCl, 
 
Final  yellow color produced after addition of HCL,  is now 
measured for adsorbance spectro-photometrically at 450 nm. The amount 
of TSH is proportional directly to the intensity of the colour obtained in  
test sample 
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CKD AND LOW T3 SYNDROME: 
 
Low T3 syndrome is the most common thyroid dysfunction noted in 
CKD patients42. Following reasons are said to be responsible for the low T3 
syndrome: 
1. The  conversion of T4 to T3 in peripheral tissues is inhibited  
By Chronic metabolic acidosis which affects deodination process. 
 
2. (TNF)-a and interleukin (IL)-1 which are abundant in CKD inhibits 
type 15’-deiodinase thereby preventing the conversion of T4 to 
T3. 
 
3. Wolff-Chaikoff effect due to impaired renal regulation of iodine 
which increases serum iodine levels2. 
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FIGURE 6 - CKD AND THYROID DISORDERS 
 
 
CLINICAL EFFECTS OF LOW T3 SYNDROME: 
The low T3 levels in CKD patients is associated with higher all-
cause as well as cardiovascular mortality. 
 But the clinical importance of T3 syndrome remains controversial 
and this association is not invariable as demonstrated by recent studies8. 
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CKD  EUTHYROID  SICK SYNDROME VS  NON-CKD  
EUTHYROID SICK SYNDROME:15 
In NON-CKD ESS there is increase in rT3 which is 
characteristically normal in CKD ESS. This can be explained by the fact 
redistribution of rT3 across vascular space in CKD patients leads to 
normal rT3 levels. But free rT3 concentrations may be high because of 
reduced renal clearance20. 
 
HYPOTHYROIDISIM IN RENAL FAILURE:3,34 
High prevalence of overt, subclinical hypothyroidism and not 
hyperthyroidism is found in CKD patients.1,14 
The Renal blood flow is decreased in hypothyroidism by decreased 
CO , raised PVR,  increased intrarenal vaso constriction, blunted renal 
response to vasodilators  such as VEGF an IGF-1 
 
Pathologic changes seen  in the glomerulus  in hypothyroidism are   
thickening of GBM  and mesangial expansion. this may also contribute to 
reduced RBF in hypothyroidism. 
           
          The GFR is reversibly decreased by 40%  in  >55% of adults with 
hypothyroidism.  
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There is reduced  sensitivity to β-adrenergic stimulus, there is 
reduced  renin  angiotensin II release from kidney which in turn  impairs 
RAAS action,  reduction of GFR.  
 
There is also a structural constraint because of limited glomerular  
filtration surface due to impaired renal parenchymal growth in 
hypothyroidism. 
 
There is a loss of  proximal tubular re-absorption of sodium, 
chloride, and water. Basolateral Cl channel expression is reduced.  
 
Impaired Cl reabsorption increases the distal Cl delivery, triggering 
the macula densa mediated feedback mechanism which inturn reduces the 
RAAS action. 
 
           The tubular transport capacity is impaired and the activity of Na/K 
ATPase is lost in the proximal tubules predominantly and later virtually in 
almost all segments of the nephron.   
 
Net reduction in sodium and bicarbonate reabsorption,  leads to 
increased loss in urine  results in reduced urinary acidification.  There is 
also an inability to maintain the medullary hypertonicity.  
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Loss of medullary hypertonicity in hypothyroidism results 
isothenuria. 
 
However, hypothyroidism raise  vasopressin sensitivity of CD 
favouring  free water reabsorption in collecting ducts. The reduced GFR, 
impaired Na reabsorption, and excess ADH secretion and ADH  mediated 
reduced free water clearance, contribute to Hyponatremia.  
 
 Hypothyroidism leads to reversible increase in Creatinine and 
reduction of cystatin c levels. 
 
Thus Hypothyroidism reduces the renal blood flow by variety of 
mechanisms including negative chronotropic and inotropic effects and 
deceased response to vasodilators. It also produces pathological changes 
in renal microanatomy like mesangial expansion and thickening of 
basement membrane. In 55% of hypothyroid patients GFR is reversibly 
reduced. 
 
Hypothyroidism also interferes with renal functions including 
decreased  absorption of sodium, chloride and water in proximal 
convoluted tubule which ultimately leads to fall in GFR by reducing 
RASS activity. 
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           Low thyroid activity also interferes with urinary acidification and 
urinary concentration mechanisms by decreased sodium and bicarbonate 
excretion and abolishing the modularly hyper tonicity respectively. 
Hypothyroidism leading to hyponatremia is well known fact, the reason for 
which is reversible increase in ADH sensitivity of collecting ducts.  
 
 
COMPLICATIONS OF CKD WORSENED BY COEXISTING 
HYPOTHYROIDISM ARE, 
I. Cardiovascular Complications 
• Secondary hypertension 
• LV failure and pulmonary edema 
• Accelerated atherosclerosis 
• Myocardial infarction 
• Pericarditis 
• Uremic cardiomyopathy 
 
          Hypothyroidism is  associated with raised LDL-c levels due to a 
reduced  LDL receptor formation in liver and impaired clearance of LDL. 
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II. CNS and neuromuscular complications 
• Dementia 
• Uremic encephalopathy 
• Peripheral neuropathy 
• Proximal muscle weakness 
 
III. Hematological complications like anemia 
             Hypothyroidism can cause normocytic normochromic, 
macrocytic anemia or iron deficiency anemia due to menorrhagia. 
 
IV. Electrolyte imbalance like hyponatremia 
            Hypothyroidism can cause euvolumic hypoosmolar hyponatremia. 
The  hyponatremia in hypothyroidism  suggests that the disease is severe- 
myxedema coma. 
 
V. Fluid overload – edema. 
            Myxedema may worsen the volume overload state of CRF 
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CHRONIC KIDNEY DISEASE  AND THYROID DYSFUNCTION 
Hyperthyroidism accelerate CKD by several mechanisms.   
hyperthyroidism increase intra-glomerular pressure that leads to glomerular 
hyperfiltration. 
 
Hyperthyroidism produces proteinuria, which  cause direct renal 
toxicity. Hyperthyroidism cause increased mitochondrial energy 
metabolism along with down-regulation of superoxide dismutase  that 
leads to the free radical production and kidney damage. Oxidative stress 
leads to hypertension  further to CKD worsening.  
 
          RAAS activity is increased that further can induce fibrosis and 
progression of CKD .  anemia exacerbated by hyperthyrodism in CKD 
patients further adds to the resistance to EPO(recombinant) 
 
 Hypothyroidism by the mild to moderate reduction in GFR it cause 
worsening in CKD. Hypothyroidism if treated appropriately it will cause  
improvement of GFR. 
  
Primary hypothyroidism is commonly observed in CKD patients. 
Esthe prevalence of subclinical hypothyroidism increases consistently with 
decline in GFR.   
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Most common  thyroid abnormality in CKD is  “low T3 syndrome” 
Fasting, acidosis and malnutrition  reduces  deiodination of iodothyronine, 
and reduces  conversion  of   T4 to T3.  TNF-a and IL-1 inhibit type 1 5′-
deiodinase, affects conversion of T4 to T3. 
 
A  prolonged Wolff – Chaikoff effect due to improper handling of 
iodine by kidneys.   
 
 
TREATMENT OF THYROID DYSFUNCTION IN CKD: 
 
            At present, there are no recommendations available regarding the 
treatment of thyroid hormone abnormalities in CRF patients.  
 
            Low thyroid state (low TT3, TT4, FT3) in uremia acts defence 
against the protein wasting and if improper attempts to replete the thyroid 
hormone stores may further worsen malnutrition in CRF patients.   
 
             But at the same time, subclinical and clinical hypothyroidism are 
associated with increased risk of cardiovascular disease and these 
conditions need treatment with thyroid hormone. 
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THYROID DYSFUNCTION IN DIALYSIS AND  KIDNEY 
TRANSPLANTATION 
 
             Patients on HD in CKD  have decreased T3 T4 and raised TSH. 
This small rise in TSH  (6 – 15 mU/l), seen in 30% of CKD patients, are 
usually not considered to be  hypothyroidism.  
 
             Total T4 is less, heparin inhibits T4 protein binding, hence freeT4 
is raised in CKD patients on heparin dialysis. In CKD patients on HD, 
compensatory cellular transport of thyroid hormones, maintains the 
euthyroid state.   
 
             Because of these reasons, inspite of serum thyroid hormone levels 
beng less,  supplemental thyroxine should not be startes without marked 
elevation in TSH level. 
 
Among patients on PD, there is increased prevalence of subclinical 
hypothyroidism and low T3 syndrome. TBG, T4, and T3 are lost in the PD 
effluent. There is continuous and marked protein loss during PD, even then 
TBG is normal.  
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T4 and T3 losses are minimal(12%  and  2%,) and thus are 
compensated without producing any effects. hence T4 replacement is not 
needed  in PD.  
 
Kidney transplantation  reverses  the CKD effects on thyroid. The 
low T3 and T4 reverse after transplant, slowly over 4–5months. In  initial 
months after transplant, there is decrease in T4 to levels lesser than the pre-
transplant level, later It rises back to normal.  
 
Post-transplant thyroid volume and fT3 levels correlate well with 
graft function.  low T3 before transplant is associated with risk of graft 
loss. 
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                        MATERIALS AND METHODS 
 
This is a prospective, Cross-sectional study conducted in teaching 
general hospital, Thanjavur Medical college, Thanjavur from 100 
consecutive Chronic kidney disease patients in medical wards and nephron 
out patient department  fulfilling  our criteria for  inclusion  and exclusion  
and those people with willingness to participate in the study were included. 
Those who were not willing to give consent for the study & too ill to 
participate are  excluded in our study. 
 
The approval for conducting the study was taken from the institutional 
ethics committee. After explaining details about the study involved, an 
informed consent is taken from the concerned participant or representative 
in case the patient is not able to provide consent. 
 
 
INCLUSION CRITERIA: 
Adult patients who fulfill the criteria for chronic kidney disease and  
who are on conservative management not undergoing renal replacement 
therapy. 
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CRITERIA FOR CHRONIC KIDNEY DISEASE:21 
                   (either of the following present for >3 months ) 
i) Markers of kidney damage (one or more ) 
 Albuminuria (AER ≥ 30mg/24 hours; ACR ≥ 30 mg/g ) 
 Using sediment abnormalities 
 Electrolyte and other abnormalities due to tubular disorders 
 Abnormalities detected by histology 
 Structural abnormalities detected by imaging  
 History of kidney transplantation 
ii) Decreased GFR                  -               GFR <60ml/min/1.73m2 
 
EXCLUSION CRITERIA : 
1. Previously diagnosed cases of hypothyroidism and hyperthyroidism 
2. Patients on Hem dialysis or Peritoneal dialysis 
3. Other condition like 
i) Patient on thyroxin  supplementation, iodine containing medications  
( amiodarone ) , anti-thyroid drugs.  
ii) Acute illness & ICU admission.  
iii) Recent Surgery or trauma. 
 
        Detailed history and examination undertaken with special focus on 
thyroid  & renal system. 
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The following investigation were done : 
1. Urine routine and microscopic examination 
2. Peripheral smear 
3. Blood urea, serum creatinine and creatinine clearance (MDRD 
formula ) 
4. Serum electrolytes including calcium and phosphorous 
5. Ultrasound abdomen 
6. FNAC in patients presenting with thyroid swelling 
7. After selecting patients fulfilling the above criteria blood sample is 
collected in non heparinised serum bottle and quantitative 
assessment of serum total T3, Free T4 and serum TSH  were done 
by Electro chemiluminescence immunoassay method 
 
NORMAL VALUES : 
Serum TSH = 0.27 – 4.2 uIU / ml  
Serum Total T3 = 0.8 – 2.0 ng / ml 
Serum Free T4 – 0.932 – 1.7 ng / dl 
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CATEGORISATION OF THYROID ABNORMALITY :11,26,30 
 
LOW T3 SYNDROME-Patients with low serum T3 levels and normal 
TSH and FT4. 
 
SUBCLINICAL HYPOTHYROIDISM : Patients with Serum TSH > 
4.20 and normal FT4 levels. 
 
HYPOTHYRODISM : Patients with Serum TSH > 4.20 and FT4 < 0.93 
 
SUBCLINICAL HYPERTHYROIDISM : Patients with Serum TSH 
<0.20 and normal FT4 levels. 
 
HYPERTHYROIDISM: Patients with Serum TSH <2.0  and FT4 > 1.7 
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                   STATISTICAL ANALYSIS 
 
The data was collected using a Performa. Data was analyzed for 
proportion of thyroid dysfunction in chronic disease patients and 
correlation of thyroid dysfunction with creatinine clearance.  
 
Statistical analysis were performed by “ Statistical Package for Social 
Sciences (SPSS) 17 software” (SPSS Inc., Chicago, IL ,USA). Pearson’s 
chi-square test and fisher test used for analysis of qualitative data.  
 
A   P value  < 0.05 was considered as statistically significant. 
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RESULTS 
100 CKD patients on conservative management who fulfilled the 
criteria were studied and the  results analyzed. 
Of 100 patients 66 (66%) were males and 34 (34%) were females. 17 
patients (17%) were 30 years and younger and 18 (18%) patients were 60 
years and above. 30-60 years age group constituted 65 (65%) patients. 
 
TABLE 2 
GENDER DISTRIBUTION 
Gender Percentage 
Male 66% 
Female 34% 
 
TABLE 3 
AGE DISTRIBUTION 
Age in yrs Percentage 
31-40 18% 
41-50 25% 
51-60 27% 
61-70 13% 
Below 30 17% 
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FIGURE 6 : 
 
 
Mean age = 46.86 ± 13.49 
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FIGURE 7: 
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TABLE 4 
CKD STAGES 
Stages of CKD Percentage 
Stage 3 18% 
Stage 4 43% 
Stage 5 39% 
 
 
In our study 18 patients (18%) were stage 3 CKD, 43 patients 
(43%) were stage 4 CKD and 39 patients (39%) belonged to stage 5 CKD. 
Creatinine clearance varied from 5.5 ti 60mi/min/1.73m2 
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FIGURE 8 : 
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SERUM CONCENTRATION OF THYROID HORMONES 
(EXCLUDING HYPOTHYROIDISM) : 
 
Serum TSH varied from 0.32 – 45 with mean of 4.71 and S.D. of 7.31 
Serum Free varied from 0.12 – 1.76 with mean of 1.31 and S.D. of 
0.26 
Serum Total T3 ranged from 0.04 to 2 with mean of 0.8 and S.D. of 0.61 
 
 
 
 
Table 5 : Serum Concentration Of Thyroid Hormones (Excluding 
Hypothyroidism ) 
Thyroid 
hormones 
Normal 
range Study range Mean 
Standard 
Deviation 
Serum TSH 
(Uiu/ml) 0.27 – 4.2 0.32 - 45 4.71 7.31 
Serum T3 
(ng/ml) 0.8 – 2.0 0.04 - 2 0.8 0.61 
Serum Free 
T4 
(ng/dl) 
0.93 – 1.71 0.12 – 1.76 0.26 0.26 
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FIGURE 9 : 
Mean and Standard Deviation of Thyroid Hormones 
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In present study overall 66 patients (66%) had thyroid dysfunction, 34 
patients (34%) had normal thyroid function tests 
 
Figure 10 :Analysis of Thyroid Dysfunction 
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ANALYSIS OF SUBTYPES OFTHYROID DYSFUNCTION : 
 
 Low T3 syndrome was the commonest thyroid dysfunction observed 
in 45 patients (45%). 3 patients (16.7%) of stage 3 CKD ,19 patients 
(44.2%) of stage 4 CKD and 23 patients (59%) of stage 5 CKD had 
low T3 syndrome. 
 Subclinical hypothyroidism was the second common thyroid 
dysfunction. It was detected in 16 patients (16%). 1 patient(5.6%) of 
stage 3, 3 patients (7.0%) of stage 4 and 12 patients (30.8%) of stage 5 
had subclinical hypothyroidism. 
 5 patients had frank hypothyroidism in our study. 3 patients (7.7%) 
were stage 5 CKD. 1 patient (2.3%) in stage 4 and 1 patient (5.6%)in 
stage 3 CKD. 
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CORRELATION OF THYROID DYSFUNCTION WITH 
CREATININE CLEARANCE : 
 
T3 LEVELS AND CREATININE CLEARANCE : 
Number of patients with low serum T3 levels increased 
proportionately with decreasing creatinine clearances with p = 0.023(S) 
 
Table 6: Serum T3 Correlation with Creatinine Clearance 
 
SERUM T3 (0.80-2.0) 
Total LOW NORMAL 
CREATININE 
CLEARANCE 
Stage 3 5 
27.8% 
9.6% 
13 
72.2% 
27.1% 
18 
100.0% 
18.0% 
Stage 4 21 
48.6% 
40.4% 
22 
51.2% 
45.8% 
43 
100.0% 
43.0% 
Stage 5 26 
66.7% 
50.05% 
13 
33.3% 
27.1% 
39 
100.0% 
39.0% 
Total  52 
52.0% 
100.0% 
48 
48.0% 
100.0% 
100 
100.0% 
100.0% 
X2  = 7.67 p= 0.023 significant  
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FT4 LEVELS AND CREATININE CLEARANCE : 
Serum FT4 levels was not significantly related to worsening renal 
function p = 0.227 (NS) 
 
TABLE 7: SERUM FREE T4 CORRELATION WITH 
CREATININECLEARANCE : 
 
 FREE T4 (0.932-1.71) 
Total 
Low Normal High 
CRETININIE 
CLEARANCE 
STAGE 3 2 
11.1% 
33.3% 
15 
83.3% 
16.3% 
1 
5.6% 
50.0% 
18 
100.0% 
18.0% 
STAGE 4 1 
2.3 
16.7% 
41 
95.3% 
44.6% 
1 
2.3 
50.0% 
43 
100.0% 
43.0% 
STAGE 5 3 
7.7% 
50.0% 
36 
92.3% 
39.1% 
0 
0% 
0% 
39 
100.0% 
39.0% 
TOTAL 
6 
6.0% 
100.0% 
92 
92.0% 
100.0% 
2 
2.0% 
100.0% 
100 
100.0% 
100.0% 
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TSH LEVELS AND CREATININE CLEARANCE : 
 Higher Serum TSH levels were found in more number of patients as 
the creatinine clearance decreased with a p = 0.004(HS) 
 
TABLE 8 : Serum TSH Correlation with Creatinine Clearance 
 SERUM TSH (0.27.4.2) Total  
Normal High 
CREATININE 
CLEARANCE 
STAGE 3 
16 
88.9% 
20.3% 
2 
11.1% 
9.5% 
18 
100.0% 
18.0% 
STAGE 4 
39 
90.7% 
49.4% 
4 
9.3% 
19.0% 
43 
100.0% 
43.0% 
STAGE 5 
24 
61.5% 
30.4% 
15 
38.5% 
71.4% 
39 
100.0% 
39.0% 
TOTAL 
79 
79.0% 
100.0% 
21 
21.0% 
100.0% 
100 
100.0% 
100.0% 
 
X2 =11.77, p=0.004, HS 
 
The proportion of CKD patients with SCH was 5.6% in stage 3,  3.7% in 
stage 4 and 30.8 in stage 5 CKD. 
The Low T3 syndrome  was found in 16.7% in CKD stage 3, 44.2% in 
stage 4 CKD and 59%in stage 5 CKD 
Hypothyroidism was found in 5.6% of stage 3CKD,  2.3%of stage 4 and 
7.7% of stage 5 CKD 
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Table 9 : Thyroid Dysfunction correlation with Creatinine Clearance 
 Types  
Normal Low T3 Sub clinical Hypo Hypo Total 
CREATININE  
CLERANCE  
STAGE 3 
13 
72.2% 
38.2% 
3 
16.7% 
6.7% 
1 
5.6% 
6.3% 
1 
5.6% 
20.0% 
18 
100.0% 
18.0% 
STAGE 4 
20 
46.5% 
58.5% 
19 
44.2% 
42.2% 
3 
7.0% 
18.8% 
12.3% 
20.0% 
43 
100.0% 
43.0% 
STAGE 5 
1 
2.6% 
2.9% 
23 
59.0% 
51.1% 
12 
30.8% 
75.0% 
3 
7.7% 
60.0% 
39 
100.0% 
39.0% 
Total  34 
34.0% 
100.0% 
45 
45.0% 
100.0% 
16 
16.0% 
100.0% 
5 
5.0% 
100.0% 
100 
100.0% 
100.0% 
 
 
Low T3 syndrome & Creatinine Clearance : x2 = 14.933, p = 0.001  (HS) 
Subclinical hypothyroidism & Creatinine Clearance : x2 = 12.875, p = 0.002 (HS) 
Hypothyroidism & Creatinine Clearance : x2 = 1.60, p = 0.449 (NS) 
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Figure 11 : Thyroid Dysfunction In Stage 3 CKD 
 
  
18
13
3
1 1
0
5
10
15
20
25
30
35
40
45
50
N
o
. 
o
f P
a
tie
n
ts
STAGE   3 CKD
No of Patients Normal
Low T3 Syndrome 2 Subclinical Hypothyroidism
Hypothyroidism
69 
 
 
 
 
Figure 12 : Thyroid Dysfunction In Stage 4 CKD 
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FIGURE 13 : Thyroid Dysfunction In Stage 5 CKD 
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Figure 14 : Thyroid Dysfunction And Correlation with Creatinine 
Clearance 
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OTHER FINDINGS  
 
ANEMIA :  76 patients (76%) were anemic with peripheral smear 
showing normocytic normochromic picture in 64 patients (84%) and 
microcytic hypochromic anemia seen in 12 patients (16%). 
 
CALCIUM &PHOSPHOROUS : Hypocalcaemia was noted in 62 
patients (62%) and hyperphosphatemia was noted in 43 patients(43%). 
 
USG abdomen revealed bilateral shrunken kidneys in 80 patients (80%), 
Hydrouretronephrosis in15 patients (15%) and normal sized kidneys in 5 
patients (5%) 
 
Thyroid swelling was found in 5 patients.   FNAC revealed multi nodular 
goiter in all 5 patients. 
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DISCUSSION 
 
The complex interplay of thyroid and renal function is highlighted 
by recent studies showing that subclinical hypothyroidism is common in 
patients with CKD22. The GFR is reduced in more than 55% of adults with 
hypothyroidism and this is reversible with treatment3. In CKD and ESRD 
patients, cardiovascular disease is the leading cause of death, accounting 
for 50% of all deaths 43. 
 
The fact that hypothyroidism is associated with raised cardiovascular  
complications and death, underscores the need for knowing the prevalence 
of thyroid dysfunction in CKD patients5. 
 
In present study we have consciously excluded patients with CKD 
undergoing dialysis because dialysis in CKD patients independently alters 
thyroid hormones as demonstrated by Rhee et al36, Ramirez et al32 . 
 
We found that 66% of CKD patients had thyroid dysfunction and 
34% had normal thyroid status. Low T3 syndrome was the commonest 
dysfunction that occurred in CKD patients on conservative management 
which is consistent with Singh et al37, Ramirez et al32, P Iglesias et 
al14,Hegedus et al13 studies. 
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In  our study 16% of CKD patients had subclinical hypothyroidism. 
A recent study by Choncholet al6 estimated 18% of CKD patients on 
conservative management had subclinical hypothyroidism. Lo et al25 found 
23% of patients with eGFR< 30 had hypothyroidism and 56% of overall 
hypothyroids were in subclinical hypothyroidism category. 
 
The present study showed 5% of patients  had frank hypothyroidism 
with clinically detectable thyroid swelling. FNAC of thyroid swelling 
showed Multi nodular goiter in all 5 patients. 
 
Detailed study by Kaptein et al estimated the prevalence of primary 
hypothyroidism to be about 2.5 times much frequent in CKD patients. A 
study by Quvionverdeet al31 estimated about 5% ESRD patients had 
hypothyroidism. 
 
Ramirez et al33 showed high prevalence of goiter in patients with 
CKD especially those on chronic dialysis. Hegeduset al13 also showed 
increased thyroid gland volume in CKD patients. 
          None of the study subjects had hyperthyroidism 
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THYROID DYSFUNCTION CORRELATION WITH eGFR : 
 
Choncholet al6, Lo et al25, in their study demonstrated an inverse 
relationship between the stage of CKD and the prevalence of Subclinical 
hypothyroidism. Chonchol et al 6 study described that prevalence of 
Subclinical hypothyroidism raised from 7% to 17.9% when eGFR was 
above 90 and below 60 respectively. 
 
Lo et al25 also showed similar results. In their study the Subclinical 
hypothyroidism prevalence was 5.4% in patients with eGFR> 90 
ml/min/1.73m2 and it increased to 23% in patients with eGFR< 30 
ml/min/1.73m2 
 
In the present study the proportion of CKD patients with Subclinical 
hypothyroidism increased from 5.6% in stage 3 to 30.8% in stage 5 with p 
value of 0.002 which is highly significant. 
 
  The patients with Low T3 syndrome increased from 16.7% in CKD 
stage 3 to 59 % in stage 5 CKD with p value of 0.001 which is highly 
significant . Hypothyroidism did not have any correlation with creatinine 
clearance. 
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LIMITATIONS OF THE STUDY 
 
This is an cross sectional study and hence it has its limitations in 
reliably establishing an causal relationship between Subclinical 
hypothyroidism and Chronic kidney disease. 
 
We did not identify the  etiology of CKD patients so the effect of 
individual disease process on thyroid dysfunction could not be studied. 
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STRENGTH OF THE STUDY  
 
1. The study was done in CKD patients who were not on dialysis which 
eliminated the dialysis induced changes in thyroid physiology. 
 
2. Free thyroxin hormone levels were used in the study as total thyroxin 
levels may be deranged in various non thyroidal diseases due to 
alteration in binding protein levels. 
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CONCLUSION 
 
1. Thyroid dysfunction occurred in 66% of Chronic Kidney Disease 
patients. 
2. Low T3 syndrome was the commonest thyroid abnormality detected. 
This can be viewed as protective mechanism to conserve protein in 
Chronic Kidney Disease patients. 
3. Subclinical hypothyroidism was the second most common thyroid 
abnormality detected. It occurred in 16% patients indicating significant 
alteration of thyroid hormone physiology in Chronic Kidney Disease 
patients. 
4. Frank hypothyroidism was the least commonly detected thyroid 
abnormality. 
5. Number of patient with Low T3 syndrome and subclinical 
hypothyroidism progressively increased with increasing severity of 
Chronic Kidney Disease. 
 
 
  
BIBLIOGRAPHY 
1. Avasthi G et al, Study of Thyroid function in patients of chronic renal 
failure. Indian Journal of Nephrology, 2001 ; 11 : 165-170 
2. Bando Y , Ushiogi Y , Okafuji K , Toya D, Tanaka N, Miura S, Non-
autoimmune primary hypothyroidism in diabetic and non-diabetic chronic 
renal dysfunction. ExpClinEndocrinol Diabetes 2002 ; 110 : 408 -415 
3. Basu, G., &Mohapatra A. Interactions between thyroid disorder and kidney 
disease. Indian Journal of Endocrinology and Metabolism. 2012 ; 16 (2) , 
204. 
4. Beckett, GJ, Henderson, CJ, Elwes, R, Seth,J&Lambie, ‘Thyroid status in 
patients with chronic-renal-failure’ Clinical Nephrology, 1983 ; vol 19, 
no.4,pg. 172-178 
5. Biondi, B., & Cooper, D. S. The clinical significance of subclinical thyroid 
dysfunction. Endocrine Reviews, 2008 ; 29(1), 76-131 
6. Chonchol, M., Lippi, G., Salvagno, G., Zoppini, G., Muggeo, M., 
&Targher, G. Prevalence of subclinical hypothyroidism in patients with 
chronic kidney disease. Clinical Journal of the American Society of 
Nephrology : CJASN, 2008 ; 3(5), 1296-1300 
7. David S. Cooper, Paul W. Ladenson, The Thyroid Gland. Greenspan’s 
Basic and Clinical Endocrinology, 9th Edison; David Gardner Dolores 
Shoback; Lange 2011 
  
8. Fernandez-Reyes MJ, Diez JJ, Collado A, Iglesias P , Bajo MA, Estrada p, 
et al. Are low concentrations of serum triiodothyronine a good marker for 
long-term mortality in hemodialysis patients, ClinNephrol 2010 ; 73 : 238-
40 
9. Ganong WF, Renal functions and micturition, Review of Medical 
Physiology 21st edition ; Mc Graw Hill : 2001, pg 702-7 
10. Ganong WF, Thyroid gland, Review of Medical physiology, 21st edition ; 
Mc Graw Hill : 2001, pg 317-324 
11. Garber, J.R., Cobin, R.H., Gharon ,H., Hennessey, J.V., Klein, I., 
Mechanick, J. I., Woeber, K. Clinical Practice Guidelines  for 
Hypothyroidism in Adults; American Association of Clinical 
Endocrinologists and the American Thyroid Association. (2012) 
12. Harrison’s principles of internal medicine 17th edition, 2008; vol 2: pg 
1761-1762. 
13. Hegedus  L et al.Thyroid gland volume and serum concentrations of 
thyroid hormone in chronic renal failure. Nephron, 1985 ; 40 : 171-4. 
14. Iglesias, P., &Diez, J.J. Thyroid dysfunction and kidney disease. European 
Journal of Endocrinology, 2009; 160 (4), 503-515. 
15. John T. Nicoloff et al. Non thyroidal illness. Degroot’s  Endocrinology,3’ 
Edition. Volume 1. 
16. KapteinEM . The Thyroid hormone metabolism and thyroid diseases in 
chronic renal failure. Endocrine Reviews 1996; 17 45-6 
  
17. Kaptein E et al. The Thyroid in end stage renal diseases, Medicine, 1988 ; 
67: 189-97 
18. Katz AI, Lindheimer MD. Renal sodium and potassium-activated 
adenosine triphosphatase and  sodium reabsorption  in the hypothyroid 
rat.JClin Invest 1973;52:796-804 
19. Keptein EM. Thyroid hormone metabolism and thyroid diseases in chronic 
renal failure. Endocrine review 1996; 17 45-63 
20. Kaptein EM, Feinstein EI, Nicoloff JT 7 Massry SG. Serum reverse 
triiodothyronine and thyroxine kinetics in patients with chronic renal 
failure. Journal of Clinical Endocrinology and Metabolism, 1983; 57 181-
189 
21. Kidney Disease : Improving Global Outcomes ( KDIGO) CKD Work 
Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and 
Management of Chronic Kidney Disease. Kidney International 
Supplements, 2013 ; 3(1).4-4. 
22. Kim, E.O., Lee, I.S., Choi, Y. a, Lee,S. J., Chang, Y. K., Hwnag, H. S. 
Unresolved subclinical hypothyroidism is independently associated with 
progression of chronic kidney disease. International Journal of Medical 
Sciences, 2014 ; 11(1), 52-9. 
23. Lim VS et al. Thyroid dysfunction in chronic renal failure. A study of the 
Pituitary thyroid axis an peripheral turnover kinetics of thyroxine and 
triiodothyroxine. J Kin Invest, 1977 ; 60 : 522-34. 
  
24. Levey,A.S., Coresh, J., Greene, T., Marsh, J., Stevens, L. A.,Kusek, J. W. 
Disease,K. Expressing the Modification of Diet in Renal Disease Study 
Equation for Estimating Glomerular Filtration Rate with Standardized 
Serum Creatinine Values, 2007 ; 772, 766-772. 
25. Lo, J. C., Chertow, G. M., Go, A. S., & Hsu, C. Y. Increased prevalence of 
subclinical and clinical hypothyroidism in persons with chronic kidney 
disease. Kidney International, 2005 ; 67(3), 1047-1052. 
26. Metha HJ et al. Total and free thyroid hormone levels in chronic renal 
failure. J Post Grad Med, 1991 ; 37 : 79-83. 
27. Miki H,  Oshimo K, Inoue H, Kawano M, Morimoto T, Monden Y, 
Yamamoto Y & Kita S. Thyroid carcinoma in patients with secondary 
hyperparathyroidism. Journal of Surgical Oncology,1992 ; 49 : 168-171. 
28. National Center for Health Statistics, Centers for Disease Control and 
Prevention. National Health and Nutrition Examination Survey. September 
2009. 
29. Oxford Textbook of Clinical Nephrology, 2nd Edition, Volume-3, The 
patient with failing renal function. 
30. Pearce, S. h. S., Brabant, G.,  Duntas, L. H., Monzani, F., Peeters, R. P., 
Razvi, S., &Wemeau,J. L., 2013 ETA Guideline: Management of 
Subclinical Hypothyroidsim. European Thyroid Journal, 2(4), 215 – 28. 
31. Quion – Verde et al. Prevalence of thyroid disease in chronic renal failure 
and dialysis patients. IXtl’ mtCongr of Nephrol, 1984 ; 120. 
  
32. Ramirez G, Jubiz, W., Gutch, C, F., Bloomer, H. A., Siegler, R., &Kolff, 
W. J. Thyroid abnormalities in renal failure: a study of 53 patients on 
chronic hemodialysis. Annals of Internal Medicine, 1973 ; 79 : 500 -4. 
33. Ramirez G, O’Neill W Jr, Jubiz W,  Bloomer HA. Thyroid dysfunction in 
uremia: Evidence for thyroid and hypophyseal abnormalities. Ann Intern 
Med, 1976 ; 84 : 672-6. 
34. Rao MB et al. Primary hypothyroidism in chronic renal failure. 
ClinNephrol, 1986 ; 25 : 11 – 4. 
35. Rhee, C. M., Alexander, E. K., Bhan, I., &Brunelli, S. M. Hypothyroidism 
and mortality among dialysis patients. Clinical Journal of the American 
Society of Nephrology,2013 ; 8(4), 593-601. 
36. Rhee, C. M., Brent, G. a., Kovesdy, C. P., Soldin, O. P., Nguyen, D., 
Budoff, M. J., Kalantar-Zadeh, K.  Thyroid functional disease : an under-
recognized cardiovascular risk factor in kidney disease patients. 
Nephrology, Dialysis, Transplantation : Official Publication of the 
European  Dialysis and Transplant Association – European Renal 
Association, 2014 ; 1- 15. 
37. Targher, G., Chonchol, M., Zoppini, G., Salvagno, G., Pichiri, I.,  
Franchini, M., & Lippi, G. Prevalence of thyroid autoimmunity and 
subcl9inical hypothyroidism in persons with chronic kidney disease not 
requiring chronic dialysis. Clinical Chemistry and Laboratory Medicine, 
2009 ; 47(11),1367-1371. 
  
38. Tisher CC, Kristen M. Anatomy of the Kidney In:BrennerBM,edition. 
Brenner and Rectors’s The Kidney, vol1  6th edition, Philadelphia; WB 
Saunders comp : 2000 p 3-67. 
39. Vaamonde CA, Sebastianelli MJ, Vaamonde LS, Pellegrini EL, Watts RS, 
Klingler EL Jr,et al. Impaired renal tubular reabsorption of sodium in 
hypothyroid man. J Lab Clin Med, 1975 ; 85 : 451-66 
40. Wilhelm Kriz, MarliesElger. Essential Renal Anatomy Comprehensive 
Clinical Nephrology (3rd Edition) edited by John Feehally, JurgenFloege& 
Richard J. Johnson.Elsevier 2015 pages 2-13. 
41. Wiederkehr MR, Kalogiros J, Krapf R. Correction of metabolic acidosis 
improves  thyroid and growth hormone axes in haemodialysis patients. 
Nephrol Dial Transplant 2004 ; 19 : 1190-7. 
42. Wheeler DC, Haynes R, Landray MJ et al. Cardiovascular aspects of 
kidney disease. In: Taal MW, Chertow  GM, Marsden PA, Skorecki K, Yu 
AS, Brenner BM (eds). Taal : Brenner and Rector’s The Kidney, 9th 
edition. Philadelphia, PA : Elsevier Saunders, 2012,pg 2060-2075 
43. Zooccali C, Tripepi G, Cutrupi S. Pizzini P, Mallamaci F. Low 
triiodothyronine : A new facet of inflammation in end- stage renal disease. 
J Am SocNephrol, 2005 ; 16 : 2789-95 
 
 
 
  
CONSENT FORM 
Name of the participant: 
Documentation of the informed consent: 
 I have read the information in this form (or it has been read to me ). I was 
free to ask any questions and they have been answered. I am over 18 years 
of age and I am exercising my free power of choice, hereby give my 
consent to be included as a participant in the study of “ A STUDY ON 
THYROID FUNCTION TESTS IN CHRONIC KIDNEY DISEASE 
PATIENTS”. The nature and purpose of data is for research work. The 
procedure has been explained to me in detail in the language 
understandable to me by the investigator. It has been made clear to me that 
all personal details like name, place, religion, past history etc., will be kept 
strictly confidential. I permit the result obtained to be also used for 
academic purpose. 
 
Thanjavur 
Date: 
Signature of the patient: 
Investigator Certificate: 
  
I certify that all the elements including the nature, purpose and possible 
risks of the above study as described in this consent document have been 
fully explained to the subject.  
Signature of the investigator: 
Date: 
Name of the Investigator: 
 
 
  
 
PATIENT INFORMATION SHEET: 
 
You are being asked to take part in a research study entitled “ A STUDY 
ON THYROID FUNCTION TESTS IN CHRONIC KIDNEY DISEASE 
PATIENTS”. 
You will not get any financial benefits from this study, but your 
participation may help future generations as it might help to find out 
proportion of the chronic kidney disease patients suffering thyroid 
dysfunction. 
Confidentiality is guaranteed. Your identity will not be revealed. You will 
have to sign a informed consent form. 
Your participation is completely voluntary. You may refuse to participate 
in the study or end your participation in the study at any time without 
penalty or loss of benefits to which you are otherwise entitled. You are free 
to ask any question during anytime of the study. We will try to answer any 
query that you may have. 
 
 
 
 
 
  
 
PROFORMA: 
NAME: 
AGE: 
SEX: 
PLACE: 
CHIEF COMPLAINTS: 
PAST MEDICAL/SURGICAL HISTORY: 
PERSONAL HISTORY: 
FAMILY HISTORY: 
GENERAL EXAMINATION: 
1. WEIGHT 
2. BMI 
3. PULSE RATE 
4. BLOOD PRESSURE 
LOCAL EXAMINATION: 
1. EYE 
2. NECK 
SYSTEMIC EXAMINATION: 
S.NO NAME IP No AGE SEX
CREATININE   
CLEARANCE
SERUM  
TSH (0.27-
4.2)
SERUM T3 
(0.80-2.0)
FREE T4 
(0932-1.71)
ANEMIA ULTRASOUND ABDOMEN
1 SELLAPAN 11458 64 M 31.9 2.2 0.32 0.12 Y B/L SHRUNKEN KIDNEYS
2 PADMINI 811 52 F 8.19 80.8 0.003 0.02 Y B/L SHRUNKEN KIDNEYS
3 RAMA SAMY 36493 60 M 5.5 10.5 1.7 1.2 Y HYDROURETERONEPHROSIS
4 BALAJI 36515 65 M 48 1.78 1.9 0.99 Y B/L SHRUNKEN KIDNEYS
5 SHOBADDERI 63016 59 F 27.65 1.3 0.098 1.43 Y B/L SHRUNKEN KIDNEYS
6 MUTHU SAMY 44447 67 M 9 0.34 0.45 1.67 Y B/L SHRUNKEN KIDNEYS
7 RAJENDRAN OP 54 M 41 0.98 0.61 1.32 Y B/L SHRUNKEN KIDNEYS
8 SANTHI 39247 39 F 11.2 37.5 0.07 0.05 Y B/L SHRUNKEN KIDNEYS
9 RAJU 11432 50 M 34.5 4 0.09 1.62 Y B/L SHRUNKEN KIDNEYS
10 KANDASAMY OP 70 M 7.18 2.8 0.6 1.05 Y HYDROURETERONEPHROSIS
11 JOSEPH 13930 63 M 7.9 9.3 1.8 1.1 Y B/L SHRUNKEN KIDNEYS
12 KAIPULLA 5190 52 M 11.9 3.4 0.43 1.54 N B/L SHRUNKEN KIDNEYS
13 ARAVINDH OP 21 M 27 3.9 0.32 1.32 Y HYDROURETERONEPHROSIS
14 RAVICHANDRAN 31029 59 M 14.3 1.7 0.65 1.56 N B/L SHRUNKEN KIDNEYS
15 PREMKUMAR OP 26 M 12.6 10.2 1.22 0.99 Y HYDROURETERONEPHROSIS
16 LAKSHMI 62980 65 M 14.9 0.99 0.09 1.32 Y B/L SHRUNKEN KIDNEYS
17 RAVI 3929 57 M 21 1.9 0.1 0.956 N B/L SHRUNKEN KIDNEYS
18 JWRAH OP 56 F 6.8 57.2 0.009 0.07 Y HYDROURETERONEPHROSIS
19 RANJITH OP 32 M 6 25.2 1.9 1.34 N NORMAL
20 VALARMATHY 40114 39 F 29 1.11 0.08 1.54 Y B/L SHRUNKEN KIDNEYS
21 THAMILSELVAN 17138 51 F 9.9 0.54 0.29 1.22 N HYDROURETERONEPHROSIS
22 SELVI OP 29 F 23.5 27.8 0.05 0.0065 Y B/L SHRUNKEN KIDNEYS
23 GOVINDARAJ 32408 53 M 5.2 15.8 1.1 1.67 N B/L SHRUNKEN KIDNEYS
24 KALYANI OP 54 F 24.7 3.2 1.38 1.21 N B/L SHRUNKEN KIDNEYS
25 SHANMUGAM OP 36 M 10.7 0.46 0.102 1.57 N HYDROURETERONEPHROSIS
26 LOGANA 320 47 F 6.3 21.6 2 1.53 Y B/L SHRUNKEN KIDNEYS
27 SUDHA 35939 29 F 22 0.56 1.8 0.99 Y B/L SHRUNKEN KIDNEYS
28 KALIYAN OP 50 M 11.9 2.43 0.32 1.32 Y HYDROURETERONEPHROSIS
29 BALASUBRAMANIYAN 16493 56 M 10.7 0.58 0.66 1.29 Y B/L SHRUNKEN KIDNEYS
30 ARUN OP 23 M 29 2.98 0.2 0.97 N B/L SHRUNKEN KIDNEYS
31 KANNAN OP 36 M 60 37.8 0.001 0.04 N B/L SHRUNKEN KIDNEYS
32 LAKSHMI OP 64 F 8.2 2.7 0.77 1.15 N HYDROURETERONEPHROSIS
33 POMA 37863 45 M 19 4 1.53 1.56 N B/L SHRUNKEN KIDNEYS
34 KANDASAMY 10483 69 M 13.5 17.3 1.29 1.54 Y NORMAL
35 SELVAKUMAR 39343 47 M 5.7 0.9 0.096 1.33 Y B/L SHRUNKEN KIDNEYS
36 VADIVAMMAL OP 49 F 47 0.32 1.38 1.27 Y HYDROURETERONEPHROSIS
37 SELVARAJ 42195 49 M 14.8 1.34 0.06 1.62 Y B/L SHRUNKEN KIDNEYS
38 KALYANI OP 26 F 13.4 9.5 1.11 1.7 Y B/L SHRUNKEN KIDNEYS
39 KARUPA SAMY OP 51 M 17 1.2 1.7 1.44 Y B/L SHRUNKEN KIDNEYS
40 VADIVAMMAL 35122 48 F 12.9 3.3 0.12 1.39 N HYDROURETERONEPHROSIS
41 THILAGAVATHI OP 61 F 53 0.9 0.91 1.5 Y B/L SHRUNKEN KIDNEYS
42 RAVICHANDRAN 39299 59 M 14.3 1.4 0.1 1.19 N B/L SHRUNKEN KIDNEYS
43 SUBBAYAN OP 52 M 28.7 2.65 1.53 1.23 Y HYDROURETERONEPHROSIS
44 DHANAM OP 65 F 12.9 2.98 0.56 1.65 N B/L SHRUNKEN KIDNEYS
MASTER CHART
45 VELLUSAMI 43203 45 M 14 1.8 0.55 1.55 Y B/L SHRUNKEN KIDNEYS
46 THIRUMAIYA OP 49 M 52 0.67 1.33 1.39 N B/L SHRUNKEN KIDNEYS
47 VIJAYA KUMAR 22890 47 M 21.2 2.88 1.49 1.22 Y B/L SHRUNKEN KIDNEYS
48 SUNDAR OP 26 M 11.1 1.7 0.004 1.24 Y B/L SHRUNKEN KIDNEYS
49 RAJAN OP 50 M 41 2 1.87 0.99 N B/L SHRUNKEN KIDNEYS
50 RENGAYAN 25336 43 M 13.6 1.4 1.23 1.5 Y B/L SHRUNKEN KIDNEYS
51 FILOMINAL OP 61 F 28.6 0.8 0.2 1.3 Y HYDROURETERONEPHROSIS
52 RAJAGAM 21655 45 M 24 2.4 0.234 1.59 N B/L SHRUNKEN KIDNEYS
53 AMUDHA 24931 47 F 9.7 12.3 1.2 1.12 Y B/L SHRUNKEN KIDNEYS
54 NAGARATTHINAM 37513 58 F 22 2.9 1.45 1.69 Y B/L SHRUNKEN KIDNEYS
55 JAYARAMAN 26834 66 M 27 4 0.1 1.38 N B/L SHRUNKEN KIDNEYS
56 KURTHAMAL OP 51 F 24.7 0.92 0.7 1.45 Y HYDROURETERONEPHROSIS
57 ANBU OP 24 M 50.2 2.67 1.56 1.1 Y B/L SHRUNKEN KIDNEYS
58 PALANI SAMY OP 53 M 17 1.02 1.37 0.98 Y B/L SHRUNKEN KIDNEYS
59 NALLI SAMI 43253 44 M 17.5 24 0.9 0.99 Y B/L SHRUNKEN KIDNEYS
60 RAVICHANDRAN 31029 57 M 18.9 1.54 1.98 1.49 Y B/L SHRUNKEN KIDNEYS
61 KUMAR OP 49 F 38 1.67 1.43 1.23 Y HYDROURETERONEPHROSIS
62 DEEPAN OP 25 M 13.3 2.15 0.07 1.7 N B/L SHRUNKEN KIDNEYS
63 RENGAYAN 25336 43 M 22.5 2.3 0.4 1.23 Y B/L SHRUNKEN KIDNEYS
64 ANITHA OP 19 F 19.83 30 1.34 1.19 Y B/L SHRUNKEN KIDNEYS
65 SELVARAJ 42195 49 M 33.9 3 1.34 1.76 N B/L SHRUNKEN KIDNEYS
66 SETHURAMAN 26941 45 M 27.1 2.1 0.67 0.976 Y B/L SHRUNKEN KIDNEYS
67 CHELLAMMAL 31251 70 F 9.7 19.4 0.9 1.03 Y B/L SHRUNKEN KIDNEYS
68 RENGASAMY OP 65 M 48.3 7.3 1.8 1.53 N B/L SHRUNKEN KIDNEYS
69 RAVI 10464 43 M 31 3.6 0.95 1.56 Y B/L SHRUNKEN KIDNEYS
70 RANI 7667 36 F 29 2.1 0.65 0.99 Y B/L SHRUNKEN KIDNEYS
71 MUTHU OP 29 M 18.43 3.5 0.99 1 N B/L SHRUNKEN KIDNEYS
72 VADIVEL OP 30 M 27.29 3.8 0.29 1.02 Y B/L SHRUNKEN KIDNEYS
73 JOSEPH 13930 61 M 20.9 2.5 1.89 1.4 Y B/L SHRUNKEN KIDNEYS
74 TAMILARASI 17138 51 F 7.7 2.3 0.095 1.49 N B/L SHRUNKEN KIDNEYS
75 ABSARALI 14455 40 M 14.3 3.9 0.89 1.52 Y B/L SHRUNKEN KIDNEYS
76 ASRAF OP 21 M 17.7 0.38 1.1 1.22 Y B/L SHRUNKEN KIDNEYS
77 NALLI 43203 42 M 16.1 0.5 1.43 1.6 Y B/L SHRUNKEN KIDNEYS
78 MARRIYAMMAL 567 28 F 8.5 4.1 0.3 1.2 Y B/L SHRUNKEN KIDNEYS
79 SELLAPAN 11458 64 M 26.54 0.45 0.77 1 Y B/L SHRUNKEN KIDNEYS
80 BALA 62966 39 M 15.2 1.89 1.87 1.09 Y B/L SHRUNKEN KIDNEYS
81 AMUTHA 24931 46 F 22.34 1.2 0.54 1.7 Y B/L SHRUNKEN KIDNEYS
82 SANKAR OP 50 M 24.6 0.77 0.38 1.46 Y B/L SHRUNKEN KIDNEYS
83 KANDASAMY 10483 69 M 51.7 3.6 0.7 1.37 Y B/L SHRUNKEN KIDNEYS
84 SELVAMANI OP 23 F 10.2 23 1.3 0.98 Y B/L SHRUNKEN KIDNEYS
85 MAYANDI OP 52 M 15.92 1.3 1.82 1.01 Y B/L SHRUNKEN KIDNEYS
86 VEERAIYAN OP 35 M 17.74 3.9 0.86 1.68 Y B/L SHRUNKEN KIDNEYS
87 FILOMINAL 536 62 F 22.65 0.47 0.54 1.05 Y B/L SHRUNKEN KIDNEYS
88 SEKAR OP 26 M 9 1.5 0.11 0.95 Y B/L SHRUNKEN KIDNEYS
89 KALYANI OP 35 F 55.5 1.125 0.93 1.42 Y B/L SHRUNKEN KIDNEYS
90 GUNASEKARAN OP 56 M 17.08 3.2 1.54 1.29 Y B/L SHRUNKEN KIDNEYS
91 VALARMATHI 40114 42 F 7.8 0.36 0.099 1.23 Y B/L SHRUNKEN KIDNEYS
92 VINOTH OP 25 M 52.6 0.9 1.5 1.47 Y NORMAL
93 MUTHU OP 34 M 19.9 4.1 1.9 1.43 Y B/L SHRUNKEN KIDNEYS
94 VANITHA OP 55 F 19.45 45 1.5 1.256 Y B/L SHRUNKEN KIDNEYS
95 DENADHAYALAN OP 43 M 42.2 1.7 1.34 0.946 Y B/L SHRUNKEN KIDNEYS
96 DINESH OP 27 M 23.21 3.88 0.65 1.73 Y B/L SHRUNKEN KIDNEYS
97 MALLIGA OP 59 F 28.76 2.9 1.26 1.27 Y B/L SHRUNKEN KIDNEYS
98 KUMUTHA OP 46 F 23.1 2.34 0.43 1.34 Y B/L SHRUNKEN KIDNEYS
99 ANBARASAN OP 54 M 22.43 0.98 0.29 1.65 Y B/L SHRUNKEN KIDNEYS
100 MURUGESAN OP 33 M 13.7 7.8 1.15 1.7 Y NORMAL
